Vertex Looks To Triple Combos For CF After Doublet Success
Top-line results from two Phase III studies indicate Vertex’s potential new combination cystic fibrosis therapy, tezacaftor plus ivacaftor, is effective and well tolerated in certain cystic fibrosis patients, and could become the backbone of a triple combination therapy for a wider patient group.
